in-Pharmatechnologist.com is in Mumbai this week for CPhI India to report news from BASF, Dow Wolff Cellulosics and Bend Research.
BASF continued the global roll out of its new line of pharma grade Omega-3 APIs in Mumbai. The drug industry conference is the second event at which the firm has showcased its new range of high purity active pharmaceutical ingredients (API) since launching the product in Madrid, Spain in early October.
The firm – which entered the pharma grade omega-3 industry earlier this year with the acquisition of Scotland-based Equateq – has been steadily building this part of its business over the last few months.
And just yesterday BASF tabled a bid for fellow manufacturer Pronova Biopharma yesterday to further expand capacity. If the deal completes, BASF will be involved in supplying several pharmaceutical companies, notably GSK and Amarin.
Dow talks spray drying in India
Dow Wolff Cellulosics, a business unit of The Dow Chemical Company, was also in Mumbai to update on its collaboration with contract formulations developer Bend Research.
The companies teamed up in October to develop effective spray-dried dispersion solutions and a selection of enabling cellulosics polymers to address the challenge of formulating poorly soluble drugs.
Dago Caceres, Global Strategic Marketing Leader for Dow Wolff Cellulosics, said: "Formulation scientists are increasingly in need of reliable and robust technology solutions to overcome this critical drug delivery issue."
"Formulation development economics have gone beyond simply using inexpensive raw materials" continued Caceres, adding "They now require cost assessments for development, scale up and manufacturing."
He also said that: "In India, the scientifically-advanced customer application development centre at Mumbai of Dow Chemical International, is at our customers’ support in the areas of Controlled Release and Immediate Release Technology.”